Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Psoriasis Registry Data Provide Evidence That Adalimumab Reduces Mortality

Key clinical point: Adalimumab therapy has been associated with reduced risk for morality in psoriasis patients.

Major finding: The all-cause mortality rate in psoriasis patients on long-term adalimumab was 58% lower than predicted in the general population.

Study details: ESPRIT is a prospective, observational, international, real-world registry including 6,014 psoriasis patients with a collective 28,161 person-years on adalimumab in routine clinical practice.

Disclosures: The ESPRIT registry is sponsored by AbbVie. The presenter reported serving as a consultant to and/or receiving research funding from that pharmaceutical company and nearly two dozen others.

Citation:

Thaci DT. EADV Congress 2019